This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kufer, P. Articles by Riethmüller, G. Search for Related Content PubMed PubMed Citation Articles by Kufer, P. Articles by Riethmüller, G.

Heterogeneous Expression of MAGE-A Genes in Occult Disseminated Tumor Cells

A Novel Multimarker Reverse Transcription-Polymerase Chain Reaction for Diagnosis of Micrometastatic Disease¹

Institute of Immunology, University of Munich, 80336 Munich, Germany [P. K., A. Z., R. L., I. M., K. P., G. R.]; Department of Urology, Dr. Horst Schmidt Kliniken, 65199 Wiesbaden, Germany [T. E., M. W. K.]; Department of Pathology, University of Chicago, Chicago, Illinois 60637 [A. M.]; Department of Urology, Zentralklinikum Augsburg, 86156 Augsburg, Germany [D. W.]; Department of Surgery, University of Munich, 80336 Munich, Germany [B. P.]; Laboratory for Molecular Oncology, 80335 Munich, Germany [N. P.]; Robert-Rössle-Klinik, Humboldt University, 13122 Berlin, Germany [P. R.]; Department of Medical Informatics, Biometrics, and Epidemiology, University of Munich, 81377 Munich, Germany [M. D.]

Systemically disseminated tumor cells have become the subject of intensive research as the presumed seminal precursors of later distant metastasis. We describe here a novel sensitive multimarker nested reverse transcription (RT)-PCR capable of detecting the individual expression of human MAGE-A genes MAGE-1, -2, -3/6, -4, and -12 by rare, disseminated tumor cells in bone marrow and blood of patients with many different types of cancer. We analyzed bone marrow aspirates from 106 patients with breast, lung, colorectal, and prostate cancer and with different sarcomas. Heterogeneous expression of the different MAGE genes was found frequently in all those kinds of malignancies, in sharp contrast to 30 bone marrow and 20 blood samples from healthy donors, which were completely MAGE negative. Expression of at least one MAGE gene in bone marrow was more frequent than cytokeratin-positive tumor cells detected by immunocytochemistry, although the results of both tests overlapped considerably. In 30 patients with clinically localized prostate cancer, analysis by the multimarker MAGE RT-PCR of bilateral bone marrow aspirates from the right and left iliac crest revealed a positivity rate of 60%, which was twice as high as that obtained with either an established prostate-specific antigen RT-PCR or by cytokeratin-based immunocytochemistry. Analysis of primary prostate cancer revealed MAGE expression patterns considerably concordant with those found in the corresponding bone marrow aspirates. Prostate cancer patients carrying an exceptionally high risk of metastatic relapse, as defined by clinical prognostic factors, were significantly more often MAGE positive than patients with a distinctly lower risk (P = 0.02, Fisher’s exact test). More frequent MAGE expression in the peripheral blood of patients with metastatic prostate cancer compared with those with clinically localized disease added further evidence for the prognostic impact of the multimarker MAGE RT-PCR. Moreover, MAGE-positive bone marrow samples from a small group of seven sarcoma patients demonstrated the relevance of our multimarker RT-PCR in nonepithelial tumors. Because MAGE antigens can induce autologous cytolytic T lymphocytes in vivo, the determination of individual MAGE expression patterns in cancer patients may furthermore identify candidate vaccine targets for adjuvant immunotherapy.

This article has been cited by other articles:

				A. Ruffato, S. Mattioli, S. Pileri, N. Daddi, F. D'Ovidio, V. Pilotti, and P. Tazzari Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 463 - 468. [Abstract] [Full Text] [PDF]

				F. Wischnewski, O. Friese, K. Pantel, and H. Schwarzenbach Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters Mol. Cancer Res., July 1, 2007; 5(7): 749 - 759. [Abstract] [Full Text] [PDF]

				W. Sienel, I. Mecklenburg, S. Dango, P. Ehrhardt, A. Kirschbaum, B. Passlick, and K. Pantel Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non-Small-Cell Lung Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3840 - 3847. [Abstract] [Full Text] [PDF]

				F. Wischnewski, K. Pantel, and H. Schwarzenbach Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells Mol. Cancer Res., May 1, 2006; 4(5): 339 - 349. [Abstract] [Full Text] [PDF]

				S Abdul-Rasool, S H Kidson, E Panieri, D Dent, K Pillay, and G S Hanekom An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J. Clin. Pathol., March 1, 2006; 59(3): 289 - 297. [Abstract] [Full Text] [PDF]

				J. Camps, G. Armengol, J. del Rey, J. J. Lozano, H. Vauhkonen, E. Prat, J. Egozcue, L. Sumoy, S. Knuutila, and R. Miro Genome-wide differences between microsatellite stable and unstable colorectal tumors Carcinogenesis, March 1, 2006; 27(3): 419 - 428. [Abstract] [Full Text] [PDF]

				T. P. Hutchinson, I. Mecklenburg, and P. Kufer Patterns of Melanoma Antigen-A Expression in Lung Cancer Patients Chest, August 1, 2005; 128(2): 1069 - 1071. [Full Text] [PDF]

				V Choesmel, F Foucault, J P Thiery, and N Blin Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation J. Clin. Pathol., December 1, 2004; 57(12): 1278 - 1287. [Abstract] [Full Text] [PDF]

				I. Mecklenburg, D. F. Stratakis, R. M. Huber, K. Haussinger, A. Morresi-Hauf, G. Riethmuller, and P. Kufer Detection of Melanoma Antigen-A Expression in Sputum and Bronchial Lavage Fluid of Patients With Lung Cancer Chest, May 1, 2004; 125(5_suppl): 164S - 166S. [Full Text] [PDF]